INVENTORY OF SUPPLEMENTARY INFORMATION Supplementary Figures
Figure S1 In vivo and in vitro specificity of the anti-Sic1-pThr 5 /-pThr 33 antibodies. T173A -expressing cells exhibit enhanced levels of Cln-/Clb-CDK activity. Tables   Table S1 . Strains used in this study Table S2 . Plasmids used in this study Table S3 . Antibodies used in this study
Supplementary

Supplementary References
Supplementary Figures
Figure S1 In vivo and in vitro specificity of the anti-Sic1-pThr 5 /-pThr 33 antibodies. (a) Sic1-pThr 5 and Sic1-pThr 33 levels were determined by immunoblot analyses using respective phospho-specific antibodies and extract of exponentially growing cells that expressed plasmid-encoded versions of myc 13 -tagged Sic1 and Sic1 T5A (left panels), or myc 13 -tagged Sic1 and Sic1 T33A (right panels). The levels of the Sic1-myc 13 variants were determined by using polyclonal anti-myc antibodies. The asterisk denotes an unspecific band. (b, c) Clb5-HA 3 -CDK immunocomplexes from exponentially growing yeast cells were used for in vitro kinase assays in which the bacterially-purified, N-terminal parts (encompassing the first 100 amino acids) of Sic1 (WT), Sic1 T5A (T5A), and Sic1 T33A (T33A) served as substrates. Sic1-pThr 5 (b) and Sic1-pThr 33 (c) levels were determined by immunoblot analyses using respective phospho-specific antibodies and the indicated GSTSic1 1-100 variants that have been phosphorylated (+), or not (-), by Clb5-HA 3 -CDK. The input levels of the GST-Sic1 1-100 variants were determined by using polyclonal anti-GST antibodies. Fig. 1A . the levels of the tagged proteins were determined by immunoblot analyses using monoclonal anti-myc or anti-HA antibodies. Adh1 levels served as loading control.
Figure S3 Cln2-HA 3 and Clb5-HA 3 interact with Cdc28 in vivo. Plasmid-expressed, HA 3 -tagged Cln2 or Clb5 were immunoprecipitated (IPed) from extracts of exponentially growing wild-type cells. Cell lysates (Input) and anti-HA immunoprecipitates (IP: anti-HA) were analyzed by immunoblotting with anti-HA (top panels), anti-Cdc28 (panels in the middle), and anti-Sic1 (bottom panels) antibodies. Please note that both Cln2-HA 3 and Clb5-HA 3 interact with Cdc28, while only Clb5-HA 3 is able to bind Sic1 as expected. Neither Cdc28 nor Sic1 were recovered in anti-HA immunoprecipitates from extracts of cells that carried an empty plasmid (-;  3 rd lanes in all panels 
Figure S4
Proliferating, Sic1 T173A -expressing cells exhibit enhanced levels of Cln-/Clb5/6-CDK activity. For synchronization, exponentially growing WT cells expressing genomically-tagged Sic1-myc 13 or Sic1 T173A -myc 13 were treated for 2 h with a-factor (5 µg ml -1 ). Following a-factor release, samples were collected at the indicated time points. The phosphorylation levels of Thr 5 in Sic1 and Sic1 T173A were determined by using phosphospecific anti-Sic1-pThr 5 antibodies and normalized with respect to the total levels (quantified by using anti-myc antibodies) of Sic1-myc 13 and Sic1 T173A -myc 13 , respectively. This study 2C pMJA3029
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